Stock listing
XNCR Stock Price, News, Filings & Events — Xencor, Inc.
Selected listing: XNCR · NASDAQ · USD · US
This page tracks Xencor, Inc.'s XNCR:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following XNCR:NASDAQ. XNCR:NASDAQ is the stock-level entry point for investors researching Xencor, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Xencor, Inc. is a public company traded on the American stock market under the ticker XNCR. The company has a market capitalization of approximately $1.3 billion. Xencor focuses on developing innovative monoclonal antibody therapies for the treatment of various diseases.
- Ticker
- XNCR:NASDAQ
- Asset type
- Stock
- Market cap
- $2.07B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Xencor, Inc. XNCR:NASDAQ stock context
This page tracks Xencor, Inc.'s XNCR:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following XNCR:NASDAQ. XNCR:NASDAQ is the stock-level entry point for investors researching Xencor, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Xencor, Inc. is a public company traded on the American stock market under the ticker XNCR. The company has a market capitalization of approximately $1.3 billion. Xencor focuses on developing innovative monoclonal antibody therapies for the treatment of various diseases.
Latest news from Xencor, Inc.
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
July 29, 2026
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell C...
July 17, 2026
Xencor Reports First Quarter 2026 Financial Results
May 6, 2026
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
May 4, 2026
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
March 4, 2026
Research Xencor, Inc.
Xencor, Inc. investor report
Review AI stock analysis and investor report context for XNCR:NASDAQ.
Xencor, Inc. company profile
View the public company page for Xencor, Inc. on 6ix.
Xencor, Inc. news
Read company news and market updates connected to Xencor, Inc..
Xencor, Inc. investor events
Find investor webinars, events, and replay context for Xencor, Inc..
Alternate listings
XE9:GETTEX
DE · EUR
Alternate listing for Xencor, Inc.; the primary context on this page is XNCR:NASDAQ.
A1W96L:LS
DE · EUR
Alternate listing for Xencor, Inc.; the primary context on this page is XNCR:NASDAQ.
A1W96L:LSX
DE · EUR
Alternate listing for Xencor, Inc.; the primary context on this page is XNCR:NASDAQ.
XNCR:BOATS
US · USD
Alternate listing for Xencor, Inc.; the primary context on this page is XNCR:NASDAQ.
XE9:TRADEGATE
DE · EUR
Alternate listing for Xencor, Inc.; the primary context on this page is XNCR:NASDAQ.
XE9:BX
CH · CHF
Alternate listing for Xencor, Inc.; the primary context on this page is XNCR:NASDAQ.
XE9:DUS
DE · EUR
Alternate listing for Xencor, Inc.; the primary context on this page is XNCR:NASDAQ.
XE9:FWB
DE · EUR
Alternate listing for Xencor, Inc.; the primary context on this page is XNCR:NASDAQ.
XE9:MUN
DE · EUR
Alternate listing for Xencor, Inc.; the primary context on this page is XNCR:NASDAQ.
XE9:SWB
DE · EUR
Alternate listing for Xencor, Inc.; the primary context on this page is XNCR:NASDAQ.